Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PCI announces definitive agreement to acquire Penn Pharma
Penn Pharma is headquartered in Tredegar, Wales in the United Kingdom and operates regional offices in New Hope, Pennsylvania and Tokyo, Japan. Penn Pharma offers both drug development
Penn Pharma is headquartered in Tredegar, Wales in the United Kingdom and operates regional offices in New Hope, Pennsylvania and Tokyo, Japan. Penn Pharma offers both drug development
Management will also quickly add new high-demand products that have been requested by buyers to round out the TapouT Muscle Growth and Recovery line. In a joint statement
The CHMP positive opinion will be reviewed by the European Commission which, should they affirm the CHMP opinion, will grant a centralized marketing authorization with unified labeling that
The foundation has a focus on promoting innovative research-based initiatives, including those addressing health issues. Lightlake has been developing a nasal spray for the delivery of naloxone that
Sunshine Biopharma anticipates that Sunshine Biopharma Canada will soon sign manufacturing, marketing, sales and distribution contracts for various pharmaceutical and biomedical products. According to various estimates, the worldwide
This operation, which will be realized in the coming weeks subject to the completion of certain usual conditions, is for Cellectis the extension to its strategic therapeutic focus.
Research shows that cannabinoids have medical application for a range of conditions as varied as epilepsy, glaucoma, osteoporosis, anorexia, Alzheimer’s disease and pain treatment. Following the recent success
U.S. Patent No. 8,765,928 entitled "Identification of isolated genomic nucleotide fragments from the p15 region of chromosome 11 encoding human tumor suppressing subtransferable candidate 4 (TSSC4) and variants
The company’s new development direction includes large molecule drugs that will address indications in diabetes and the overall metabolic syndrome. The company’s sub-micron technology allows for development of
Three months after its authorization by the ANSM, the French authority for drug safety, a first patient has been enrolled. Having already successfully completed a Phase I study